<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_therapeutic" title="STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma" shortTitle="therapeutic" author="Carol Lee, Siu  Tim Cheung" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2072-6694/11/11/1646/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
</s>
<s type="frag">
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
Primary	JJ	Primary
liver	NN	liver
cancer	NN	cancer
is	VBZ	be
the	DT	the
sixth	JJ	sixth
most	RBS	most
prevalent	JJ	prevalent
cancer	NN	cancer
and	CC	and
the	DT	the
second	JJ	second
leading	VBG	lead
cause	NN	cause
of	IN	of
cancer	NN	cancer
mortality	NN	mortality
worldwide	RB	worldwide
.	.	.
</s>
<s type="decl">
The	DT	the
most	RBS	most
common	JJ	common
primary	JJ	primary
liver	NN	liver
cancer	NN	cancer
is	VBZ	be
hepatocellular	JJ	hepatocellular
carcinoma	NN	carcinoma
(	-LRB-	(
HCC	NNP	HCC
)	-RRB-	)
,	,	,
which	WDT	which
accounts	VBZ	account
for	IN	for
&gt;85	CD	&gt;85
%	NN	%
of	IN	of
all	DT	all
cases	NNS	case
.	.	.
</s>
<s type="decl">
HCC	NNP	HCC
predominantly	RB	predominantly
arises	VBZ	arise
in	IN	in
the	DT	the
setting	NN	setting
of	IN	of
cirrhosis	NN	cirrhosis
associated	VBN	associate
with	IN	with
hepatitis	NNP	hepatitis
B	NNP	B
and	CC	and
C	NNP	C
virus	NN	virus
infections	NNS	infection
,	,	,
alcohol	NN	alcohol
abuse	NN	abuse
,	,	,
non-alcoholic	JJ	non-alcoholic
steatohepatitis	NN	steatohepatitis
and	CC	and
metabolic	JJ	metabolic
diseases	NNS	disease
.	.	.
</s>
<s type="decl">
Early-stage	JJ	Early-stage
HCC	NN	HCC
patients	NNS	patient
are	VBP	be
often	RB	often
subjected	VBN	subject
to	IN	to
surgical	JJ	surgical
resection	NN	resection
and	CC	and
liver	NN	liver
transplantation	NN	transplantation
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
5-year	NN	5-year
recurrence	NN	recurrence
rates	NNS	rate
after	IN	after
resection	NN	resection
reach	VBP	reach
&gt;70	CD	&gt;70
%	NN	%
and	CC	and
the	DT	the
efficiency	NN	efficiency
of	IN	of
transplantation	NN	transplantation
is	VBZ	be
limited	VBN	limit
by	IN	by
organ	JJ	organ
shortage	NN	shortage
and	CC	and
technical	JJ	technical
issues	NNS	issue
.	.	.
</s>
<s type="decl">
Although	IN	although
local	JJ	local
ablation	NN	ablation
and	CC	and
transarterial	JJ	transarterial
chemoembolization	NN	chemoembolization
respectively	RB	respectively
confer	VBP	confer
5-year	JJ	5-year
survival	NN	survival
rates	NNS	rate
of	IN	of
50	CD	50
â€“	SYM	-
70	CD	70
%	NN	%
and	CC	and
survival	NN	survival
benefit	NN	benefit
of	IN	of
&gt;6	CD	&gt;6
months	NNS	month
,	,	,
they	PRP	they
are	VBP	be
confined	VBN	confine
to	IN	to
patients	NNS	patient
with	IN	with
single	JJ	single
tumors	NNS	tumor
or	CC	or
multinodular	JJ	multinodular
tumors	NNS	tumor
with	IN	with
good	JJ	good
liver	NN	liver
reserve	NN	reserve
.	.	.
</s>
<s type="decl">
Chemotherapy	NN	chemotherapy
is	VBZ	be
not	RB	not
routinely	RB	routinely
used	VBN	use
due	JJ	due
to	IN	to
the	DT	the
chemoresistant	JJ	chemoresistant
character	NN	character
of	IN	of
HCC	NNP	HCC
.	.	.
</s>
<s type="decl">
For	IN	for
advanced	JJ	advanced
HCC	NNP	HCC
,	,	,
sorafenib	NN	sorafenib
,	,	,
a	DT	a
multi-tyrosine	JJ	multi-tyrosine
kinase	NN	kinase
inhibitor	NN	inhibitor
(	-LRB-	(
MTKI	NNP	MTKI
)	-RRB-	)
,	,	,
has	VBZ	have
been	VBN	be
the	DT	the
only	JJ	only
approved	VBN	approve
systemic	JJ	systemic
first-line	JJ	first-line
agent	NN	agent
for	IN	for
over	IN	over
a	DT	a
decade	NN	decade
,	,	,
until	IN	until
lenvatinib	NN	lenvatinib
,	,	,
another	DT	another
MTKI	NNP	MTKI
,	,	,
recently	RB	recently
came	VBD	come
into	IN	into
play	NN	play
.	.	.
</s>
<s type="decl">
Yet	RB	yet
,	,	,
their	PRP$	their
clinical	JJ	clinical
efficacy	NN	efficacy
was	VBD	be
suboptimal	JJ	suboptimal
,	,	,
with	IN	with
only	RB	only
~3	CD	~3
months	NNS	month
of	IN	of
prolonged	JJ	prolonged
survival	NN	survival
.	.	.
</s>
<s type="decl">
Second-line	JJ	Second-line
treatments	NNS	treatment
include	VBP	include
regorafenib	NN	regorafenib
and	CC	and
cabozantinib	NN	cabozantinib
,	,	,
also	RB	also
MTKIs	NNP	Mtkis
;	:	;
nivolumab	NN	nivolumab
and	CC	and
pembrolizumab	NN	pembrolizumab
,	,	,
immune	JJ	immune
checkpoint	NN	checkpoint
inhibitors	NNS	inhibitor
targeting	VBG	target
programmed	VBN	programme
death-1	NN	death-1
(	-LRB-	(
PD-1	NNP	PD-1
)	-RRB-	)
;	:	;
and	CC	and
ramucirumab	NN	ramucirumab
,	,	,
the	DT	the
first	JJ	first
biomarker-driven	JJ	biomarker-driven
therapeutics	NNS	therapeutics
approved	VBN	approve
for	IN	for
HCC	NNP	HCC
that	WDT	that
targets	VBZ	target
the	DT	the
angiogenic	JJ	angiogenic
vascular	JJ	vascular
endothelial	NN	endothelial
growth	NN	growth
factor	NN	factor
receptor	NN	receptor
(	-LRB-	(
VEGFR	NNP	VEGFR
)	-RRB-	)
,	,	,
all	DT	all
of	IN	of
which	WDT	which
have	VBP	have
not	RB	not
been	VBN	be
established	VBN	establish
until	IN	until
the	DT	the
past	JJ	past
few	JJ	few
years	NNS	year
and	CC	and
require	VBP	require
further	JJ	further
investigations	NNS	investigation
.	.	.
</s>
<s type="decl">
So	RB	so
far	RB	far
,	,	,
treatment	NN	treatment
outcomes	NNS	outcome
for	IN	for
HCC	NNP	HCC
are	VBP	be
far	RB	far
from	IN	from
satisfactory	JJ	satisfactory
,	,	,
with	IN	with
a	DT	a
5-year	JJ	5-year
survival	NN	survival
rate	NN	rate
of	IN	of
only	RB	only
~18	JJ	~18
%	NN	%
.	.	.
</s>
<s type="decl">
Evidently	RB	evidently
,	,	,
there	EX	there
is	VBZ	be
an	DT	a
urgent	JJ	urgent
need	NN	need
to	TO	to
develop	VB	develop
more	RBR	more
effective	JJ	effective
therapeutic	JJ	therapeutic
strategies	NNS	strategy
in	IN	in
HCC	NNP	HCC
.	.	.
</s>
</p>
<p>
<s type="decl">
Signal	NN	signal
transducer	NN	transducer
and	CC	and
activator	NN	activator
of	IN	of
transcription	NN	transcription
3	CD	3
(	-LRB-	(
STAT3	NNP	STAT3
)	-RRB-	)
has	VBZ	have
recently	RB	recently
emerged	VBN	emerge
as	IN	as
a	DT	a
potential	JJ	potential
therapeutic	JJ	therapeutic
target	NN	target
for	IN	for
HCC	NNP	HCC
due	JJ	due
to	IN	to
its	PRP$	its
crucial	JJ	crucial
roles	NNS	role
in	IN	in
oncogenesis	NN	oncogenesis
.	.	.
</s>
<s type="decl">
STAT3	NNP	STAT3
was	VBD	be
initially	RB	initially
determined	VBN	determine
to	TO	to
control	VB	control
acute-phase	JJ	acute-phase
genes	NNS	gene
in	IN	in
response	NN	response
to	IN	to
interleukin-6	NN	interleukin-6
(	-LRB-	(
IL-6	NNP	IL-6
)	-RRB-	)
and	CC	and
epidermal	NN	epidermal
growth	NN	growth
factor	NN	factor
(	-LRB-	(
EGF	NNP	EGF
)	-RRB-	)
during	IN	during
inflammation	NN	inflammation
.	.	.
</s>
<s type="decl">
It	PRP	it
belongs	VBZ	belong
to	IN	to
the	DT	the
STAT	NNP	STAT
family	NN	family
of	IN	of
cytoplasmic	JJ	cytoplasmic
transcription	NN	transcription
factors	NNS	factor
that	WDT	that
mediate	VBP	mediate
signal	NN	signal
transduction	NN	transduction
from	IN	from
the	DT	the
plasma	NN	plasma
membrane	NN	membrane
to	IN	to
the	DT	the
nucleus	NN	nucleus
in	IN	in
various	JJ	various
cellular	JJ	cellular
activities	NNS	activity
.	.	.
</s>
<s type="decl">
The	DT	the
STAT	NNP	STAT
family	NN	family
comprises	VBZ	comprise
seven	CD	7
members	NNS	member
:	:	:
STAT1	NNP	STAT1
,	,	,
2	CD	2
,	,	,
3	CD	3
,	,	,
4	CD	4
,	,	,
5a	CD	5a
,	,	,
5b	CD	5b
and	CC	and
6	CD	6
.	.	.
</s>
<s type="decl">
Each	DT	each
of	IN	of
them	PRP	they
consists	VBZ	consist
of	IN	of
(	NN	(
i	CD	I
)	-RRB-	)
an	DT	a
N-terminal	JJ	N-terminal
domain	NN	domain
for	IN	for
oligomerization	NN	oligomerization
,	,	,
(	-LRB-	(
ii	CD	ii
)	-RRB-	)
a	DT	a
coiled-coil	JJ	coiled-coil
domain	NN	domain
for	IN	for
interaction	NN	interaction
with	IN	with
regulatory	JJ	regulatory
proteins	NNS	protein
,	,	,
(	:	(
iii	CD	iii
)	-RRB-	)
a	DT	a
DNA-binding	NN	DNA-binding
domain	NN	domain
for	IN	for
recognition	NN	recognition
of	IN	of
specific	JJ	specific
DNA	NN	DNA
sequences	NNS	sequence
,	,	,
(	:	(
iv	CD	iv
)	-RRB-	)
a	DT	a
Src	NNP	Src
homology-2	NN	homology-2
(	-LRB-	(
SH2	NNP	SH2
)	-RRB-	)
domain	NN	domain
that	WDT	that
triggers	VBZ	trigger
phosphorylation	NN	phosphorylation
and	CC	and
dimerization	NN	dimerization
after	IN	after
docking	NN	docking
to	IN	to
phosphorylated	JJ	phosphorylated
receptors	NNS	receptor
and	CC	and
(	:	(
iv	CD	iv
)	-RRB-	)
a	DT	a
C-terminal	JJ	C-terminal
transactivation	NN	transactivation
domain	NN	domain
with	IN	with
specific	JJ	specific
tyrosine	NN	tyrosine
(	-LRB-	(
Y	CD	Y
)	-RRB-	)
(	-LRB-	(
present	JJ	present
in	IN	in
all	DT	all
STATs	NNS	Stat
)	-RRB-	)
and	CC	and
serine	NN	serine
(	-LRB-	(
S	FW	S
)	-RRB-	)
residues	NNS	residue
(	-LRB-	(
absent	JJ	absent
in	IN	in
STAT2	NNP	STAT2
and	CC	and
6	CD	6
)	-RRB-	)
that	WDT	that
are	VBP	be
phosphorylated	VBN	phosphorylate
upon	IN	upon
transcriptional	JJ	transcriptional
activation	NN	activation
.	.	.
</s>
</p>
<p>
<s type="decl">
Intensive	JJ	Intensive
investigation	NN	investigation
has	VBZ	have
been	VBN	be
done	VBN	do
on	IN	on
STAT3	NNP	STAT3
since	IN	since
its	PRP$	its
discovery	NN	discovery
,	,	,
revealing	VBG	reveal
its	PRP$	its
physiological	JJ	physiological
roles	NNS	role
in	IN	in
early	JJ	early
embryonic	JJ	embryonic
development	NN	development
,	,	,
growth	NN	growth
and	CC	and
differentiation	NN	differentiation
of	IN	of
various	JJ	various
adult	JJ	adult
tissues	NNS	tissue
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
its	PRP$	its
pathogenic	JJ	pathogenic
roles	NNS	role
in	IN	in
cancer	NN	cancer
initiation	NN	initiation
,	,	,
progression	NN	progression
,	,	,
metastasis	NN	metastasis
,	,	,
chemoresistance	NN	chemoresistance
and	CC	and
immunoevasion	NN	immunoevasion
have	VBP	have
been	VBN	be
uncovered	VBN	uncover
.	.	.
</s>
<s type="decl">
To	IN	to
date	NN	date
,	,	,
STAT3	NNP	STAT3
is	VBZ	be
widely	RB	widely
recognized	VBN	recognize
as	IN	as
an	DT	a
oncogenic	JJ	oncogenic
factor	NN	factor
in	IN	in
diverse	JJ	diverse
human	JJ	human
cancers	NNS	cancer
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
targeting	VBG	target
STAT3	NNP	STAT3
might	MD	might
be	VB	be
an	DT	a
attractive	JJ	attractive
therapeutic	JJ	therapeutic
strategy	NN	strategy
for	IN	for
HCC	NNP	HCC
treatment	NN	treatment
.	.	.
</s>
<s type="decl">
In	IN	in
this	DT	this
review	NN	review
,	,	,
we	PRP	we
summarize	VBP	summarize
the	DT	the
oncogenic	JJ	oncogenic
roles	NNS	role
of	IN	of
STAT3	NNP	STAT3
in	IN	in
HCC	NNP	HCC
and	CC	and
the	DT	the
current	JJ	current
clinical	JJ	clinical
development	NN	development
of	IN	of
STAT3-targeted	NNP	STAT3-targeted
therapeutics	NNS	therapeutics
.	.	.
</s>
</p>
</text>